Current Report Filing (8-k)
March 13 2017 - 12:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported)
|
|
March 7, 2017
|
Accelerate
Diagnostics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-31822
|
84-1072256
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
3950 South Country Club, Suite 470, Tucson, Arizona
|
85714
|
(Address of principal executive offices)
|
(Zip Code)
|
(520) 365-3100
|
(Registrant’s telephone number, including area code)
|
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On March 7, 2017, the Board of Directors
(the “Board”) of Accelerate Diagnostics, Inc. (the “Company”) determined that, in connection with the Company
obtaining United States Food and Drug Administration approval and commencing global commercialization of its Accelerate Pheno
TM
system and Accelerate PhenoTest
TM
BC kit, the scope of responsibilities and independent decision-making authority of
Ron Price, Senior Vice President and Head of Commercial Operations, Americas, and Joan Martin, Executive Vice President & Head
of Europe, Middle East, and Africa, have changed, and therefore, the Board designated both as executive officers of the Company,
as defined in Rule 3b-7 of the Securities Exchange Act of 1934, as amended (the “Act”). In addition, the Board also
determined that Pete Bantock, Chief Culture Officer and Head of Human Resources of the Company, is no longer an executive officer
of the Company, as defined in Rule 3b-7 of the Act.
Mr. Price, 53, has served as Senior Vice
President and Head of Commercial Operations, Americas since April 2015. Mr. Price has over 20 years of commercial operations experience
and a proven track record of leading sales and marketing teams to achieve double-digit revenue growth and strong bottom-line performance.
Prior to joining the Company, Mr. Price served as Vice President, Commercial Operations for Roche Point of Care managing all commercial
responsibilities across three separate product lifecycles. In addition, Mr. Price held a number of sales, marketing, and leadership
roles with Ventana Medical Systems from 2001 to 2012 following 5 years at Bayer Healthcare Diagnostics. Mr. Price holds a B.S.
in Clinical Laboratory Sciences, Cytology from the University of Oklahoma.
Mr. Martin, 48, has served as Executive
Vice President and Head of Europe, Middle East, and Africa since July 2015. Prior to joining the Company, Mr. Martin served as
Senior Vice President at Siemens Healthcare beginning in 2008 including broad geographical responsibility for European, Middle-Eastern,
and African territories for In Vitro Diagnostics, and Imaging Products and Solutions. From 2001 until 2007, Mr. Martin worked for
Dade Behring as Vice President and General Manager for Southeast Europe, France, and Belgium and also as Finance & Operations
Director, EMEA from 2001 until 2004. Mr. Price also worked as Finance Director for a number of leading multinational companies
and Senior Auditor at Coopers & Lybrand, presently PwC. Mr. Martin holds a degree in Economics and Business from the University
of Barcelona, Spain.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ACCELERATE DIAGNOSTICS, INC.
|
|
(Registrant)
|
|
|
|
Date: March 13,
2017
|
/s/ Steve
Reichling
|
|
|
Steve Reichling
|
|
Chief Financial Officer
|
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accelerate Diagnostics (NASDAQ:AXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024